Cooper Companies (NASDAQ:COO) Price Target Raised to $78.00

Cooper Companies (NASDAQ:COO) had its price target raised by JPMorgan Chase & Co. from $66.00 to $78.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a neutral rating on the medical device company’s stock.

Other equities analysts have also recently issued research reports about the company. Stifel Nicolaus set a $95.00 price target on Cooper Companies and gave the company a “buy” rating in a report on Friday. Barclays began coverage on shares of Cooper Companies in a research report on Monday, October 13th. They set an “overweight” rating and a $85.00 target price for the company. The Goldman Sachs Group set a $64.00 target price on Cooper Companies and gave the stock a “sell” rating in a report on Wednesday, October 1st. Weiss Ratings reissued a “hold (c-)” rating on shares of Cooper Companies in a report on Monday, December 1st. Finally, Wells Fargo & Company reiterated an “equal weight” rating and issued a $72.00 price objective on shares of Cooper Companies in a research report on Thursday, November 13th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Cooper Companies currently has a consensus rating of “Moderate Buy” and a consensus target price of $90.31.

Cooper Companies Stock Up 5.7%

Shares of Cooper Companies stock opened at $81.40 on Friday. The stock has a 50-day simple moving average of $72.29 and a 200-day simple moving average of $71.61. Cooper Companies has a 52-week low of $61.78 and a 52-week high of $101.53. The firm has a market cap of $16.18 billion, a price-to-earnings ratio of 43.30, a P/E/G ratio of 1.94 and a beta of 1.05. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.89 and a quick ratio of 1.13.

Cooper Companies (NASDAQ:COO) last announced its earnings results on Thursday, December 4th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.11 by $0.04. Cooper Companies had a return on equity of 10.02% and a net margin of 9.16%.The firm had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.06 billion. During the same quarter in the prior year, the business earned $1.04 earnings per share. The company’s revenue was up 4.6% on a year-over-year basis. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. On average, equities research analysts expect that Cooper Companies will post 3.98 earnings per share for the current fiscal year.

Cooper Companies declared that its board has authorized a share repurchase plan on Wednesday, September 17th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical device company to reacquire up to 15.4% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s management believes its shares are undervalued.

Insider Buying and Selling at Cooper Companies

In related news, Director Lawrence Erik Kurzius bought 2,000 shares of the stock in a transaction that occurred on Monday, September 29th. The shares were acquired at an average price of $68.39 per share, with a total value of $136,780.00. Following the completion of the transaction, the director owned 5,777 shares in the company, valued at $395,089.03. The trade was a 52.95% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.98% of the stock is owned by insiders.

Institutional Investors Weigh In On Cooper Companies

Several large investors have recently made changes to their positions in the stock. Wellington Management Group LLP increased its holdings in Cooper Companies by 332.9% during the third quarter. Wellington Management Group LLP now owns 6,184,992 shares of the medical device company’s stock worth $424,043,000 after buying an additional 4,756,178 shares during the last quarter. Sustainable Growth Advisers LP acquired a new position in shares of Cooper Companies during the 2nd quarter worth about $240,881,000. JANA Partners Management LP bought a new stake in shares of Cooper Companies in the 3rd quarter valued at about $166,917,000. Capital World Investors raised its holdings in shares of Cooper Companies by 25.7% in the 3rd quarter. Capital World Investors now owns 10,551,592 shares of the medical device company’s stock valued at $723,417,000 after purchasing an additional 2,159,233 shares during the period. Finally, Ameriprise Financial Inc. lifted its stake in Cooper Companies by 98.8% in the 2nd quarter. Ameriprise Financial Inc. now owns 3,388,413 shares of the medical device company’s stock valued at $241,120,000 after purchasing an additional 1,683,561 shares during the last quarter. Institutional investors and hedge funds own 24.39% of the company’s stock.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.